Retatrutide vs Semaglutide: Comparing Weight Loss Results

Semaglutide has dominated the medical weight loss landscape since its approval for chronic weight management in 2021. With semaglutide therapy now widely available, a newer contender called retatrutide has emerged from clinical trials with results that could redefine what is possible with anti-obesity medications. Both medications work through incretin hormone pathways, but their mechanisms, clinical results, and availability differ substantially.

This comprehensive comparison examines how retatrutide and semaglutide stack up across every dimension that matters: mechanism of action, weight loss results, side effects, availability, cost considerations, and who each medication is best suited for.

Understanding the Fundamentals

What Is Semaglutide?

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist developed by Novo Nordisk. It mimics the natural GLP-1 hormone, which is released from the gut after eating and plays a central role in appetite regulation and blood sugar control.

Semaglutide is available under several brand names:

• Ozempic: FDA-approved for type 2 diabetes (doses up to 2 mg weekly)
• Wegovy: FDA-approved for chronic weight management (doses up to 2.4 mg weekly)
• Rybelsus: Oral tablet form approved for type 2 diabetes

Semaglutide has the most extensive clinical evidence of any GLP-1 medication for weight loss, with the STEP trial program providing robust data across multiple patient populations. The SELECT cardiovascular outcomes trial further demonstrated a 20% reduction in major adverse cardiovascular events in overweight and obese adults (Lincoff et al., 2023).

What Is Retatrutide?

Retatrutide (development name LY3437943) is an investigational medication developed by Eli Lilly and Company. It represents a new class of drugs: triple hormone receptor agonists. Unlike semaglutide, which targets a single receptor, retatrutide simultaneously activates three metabolic pathways.

As of early 2026, retatrutide is in Phase 3 clinical trials and has not yet received FDA approval. The Phase 2 results published in The New England Journal of Medicine generated enormous interest due to unprecedented weight loss outcomes (Jastreboff et al., 2023).

How They Work: Mechanism of Action

The fundamental difference between these medications lies in how many metabolic pathways they engage.

Semaglutide: Single-Receptor Approach

Semaglutide activates the GLP-1 receptor, producing the following effects:

• Appetite suppression through direct action on hypothalamic neurons that control hunger signaling
• Delayed gastric emptying that promotes prolonged feelings of fullness after meals
• Enhanced glucose-dependent insulin secretion from pancreatic beta cells
• Reduced glucagon secretion (different from glucagon receptor activation) that lowers hepatic glucose output
• Potential neuroprotective effects currently being studied in Alzheimer’s disease trials

Research by Blundell et al. (2017) published in Diabetes, Obesity and Metabolism demonstrated that semaglutide specifically reduces appetite, food cravings, and the desire to eat energy-dense foods through central nervous system mechanisms.

Retatrutide: Triple-Receptor Approach

Retatrutide activates all three of the following receptors simultaneously:

GLP-1 Receptor (shared with semaglutide):

• Appetite suppression and delayed gastric emptying
• Improved insulin secretion and blood sugar regulation

GIP Receptor (shared with tirzepatide):

• Enhanced insulin sensitivity in adipose tissue
• Improved lipid metabolism and nutrient partitioning
• Potential direct effects on fat cell biology that promote fat mobilization
• Research in Cell Metabolism has shown GIP signaling plays critical roles in adipose tissue function (Campbell & Drucker, 2015)

Glucagon Receptor (unique to retatrutide):

• Increased resting energy expenditure through thermogenesis
• Enhanced hepatic fat oxidation promoting the breakdown of stored fat
• Lipolysis stimulation that mobilizes fatty acids from adipose tissue
• A review in Diabetes, Obesity and Metabolism described glucagon agonism as uniquely capable of increasing caloric burn independent of reduced food intake (Pocai, 2014)

The glucagon receptor component is what truly distinguishes retatrutide. While semaglutide works primarily by reducing how much you eat, retatrutide simultaneously reduces intake and increases how many calories your body burns. This dual approach — eating less and burning more — may explain the superior weight loss results observed in clinical trials.

Weight Loss Results: Head-to-Head Data

Semaglutide Clinical Trial Results

The STEP (Semaglutide Treatment Effect in People with Obesity) trial program is the most comprehensive dataset for any anti-obesity medication:

STEP 1 (Wilding et al., 2021, NEJM):

• 1,961 adults with obesity (BMI 30+) or overweight (BMI 27+) with comorbidities
• Semaglutide 2.4 mg weekly vs. placebo
• Average weight loss: 14.9% over 68 weeks (vs. 2.4% placebo)
• 86.4% of participants lost at least 5% of body weight
• 69.1% lost at least 10%
• 50.5% lost at least 15%

STEP 3 (Wadden et al., 2021, JAMA):

• Combined with intensive behavioral therapy
• Average weight loss: 16.0% over 68 weeks
• Demonstrated that lifestyle support amplifies medication effects

STEP 5 (Garvey et al., 2022, Nature Medicine):

• Two-year duration study
• Average weight loss: 15.2% maintained over 104 weeks
• Demonstrated sustained effectiveness with continued use

Retatrutide Clinical Trial Results

Phase 2 Trial (Jastreboff et al., 2023, NEJM):

• 338 adults with obesity (BMI 30+) or overweight (BMI 27+) with comorbidities
• Multiple dose groups (1 mg, 4 mg, 8 mg, 12 mg weekly)
• Results at the 12 mg dose:
  • Average weight loss: 24.2% in 48 weeks
  • 100% of participants lost at least 5% of body weight
  • 93% lost at least 10%
  • 83% lost at least 15%
  • 63% lost at least 20%
  • Weight loss trajectory had not plateaued at study end

Comprehensive Comparison Table

Feature	Semaglutide (Wegovy)	Retatrutide
Developer	Novo Nordisk	Eli Lilly
Receptor Targets	GLP-1	GLP-1 + GIP + Glucagon
Mechanism	Appetite suppression	Appetite suppression + increased energy expenditure
Average Weight Loss	14.9% (68 weeks)	24.2% (48 weeks)
Participants Losing 5%+	86.4%	100%
Participants Losing 15%+	50.5%	83%
FDA Approval	Yes (2021)	Not yet (Phase 3 trials ongoing)
Administration	Weekly subcutaneous injection	Weekly subcutaneous injection
Cardiovascular Data	SELECT trial: 20% MACE reduction	Not yet available
Long-Term Safety Data	Extensive (5+ years)	Limited (Phase 2 only)
Current Availability	Widely available	Clinical trials only
Insurance Coverage	Variable by plan	Not applicable
Type 2 Diabetes Indication	Yes (as Ozempic)	Being studied

Side Effects Comparison

Both medications share similar gastrointestinal side effect profiles because they both activate GLP-1 receptors. However, there are important differences.

Semaglutide Side Effects (Well-Established)

Common (from STEP trial data):

• Nausea (44%)
• Diarrhea (30%)
• Vomiting (24%)
• Constipation (24%)
• Abdominal pain (20%)
• Headache (14%)

Serious but rare:

• Pancreatitis
• Gallbladder events (increased with rapid weight loss)
• Thyroid C-cell tumors (boxed warning based on animal studies)

Most GI side effects are dose-dependent and improve with continued use. The STEP trials showed that symptoms were most pronounced during the 16-week titration period and diminished significantly once participants reached their maintenance dose (Wilding et al., 2021).

Retatrutide Side Effects (Preliminary Data)

Common (from Phase 2 data):

• Nausea (25-45% depending on dose)
• Diarrhea (20-35%)
• Vomiting (10-20%)
• Constipation (10-15%)
• Decreased appetite

Notable differences:

• Mild increases in resting heart rate observed
• The glucagon receptor component may introduce metabolic effects not seen with GLP-1-only medications
• Full safety profile awaiting Phase 3 data

The overall tolerability of retatrutide in the Phase 2 trial was described as acceptable, with most adverse events being mild to moderate. Proper dose titration was key to minimizing side effects (Jastreboff et al., 2023).

Muscle Preservation: A Critical Consideration

One concern with any rapid weight loss medication is the loss of lean muscle mass alongside fat. This is clinically important because muscle loss can reduce metabolic rate, impair functional capacity, and worsen long-term outcomes.

Semaglutide and Body Composition

Data from the STEP trials indicates that approximately 39% of weight lost with semaglutide comes from lean mass, with the remainder from fat mass. A sub-study using DEXA scanning published in Nature Medicine confirmed this ratio (Wilding et al., 2021). While this lean mass loss is proportional to the total weight loss and generally considered acceptable, it underscores the importance of resistance training and adequate protein intake during treatment. Patients with low testosterone may face an even greater risk of muscle loss and should have hormone levels evaluated before starting treatment.

Retatrutide and Body Composition

Detailed body composition data from the retatrutide Phase 2 trial has not been fully published. However, the glucagon receptor component offers a theoretical advantage. By increasing resting energy expenditure through thermogenesis and fat oxidation, retatrutide may promote preferential fat loss while relatively sparing lean mass. This hypothesis requires confirmation in larger trials with body composition endpoints.

Regardless of which medication is used, structured medical weight loss programs that include resistance training at least two to three times per week and protein intake of 1.2 to 1.6 grams per kilogram of body weight per day are essential to minimize muscle loss during pharmacologically assisted weight loss.

Availability and Access

Semaglutide

Semaglutide is widely available by prescription in the United States and internationally. As of 2026:

• Branded options (Wegovy, Ozempic) are available through most pharmacies
• Compounded semaglutide is available through licensed compounding pharmacies
• Insurance coverage varies significantly by plan; many plans now cover Wegovy for weight management
• Out-of-pocket costs range from approximately $200-500 per month (compounded) to $800-1,300+ per month (branded without insurance)

Retatrutide

Retatrutide is not yet commercially available. Access is limited to:

• Clinical trial participation through active Eli Lilly Phase 3 studies
• Some compounding pharmacies (regulatory gray area; proceed with caution)
• Research chemical vendors (not recommended; safety concerns)

The timeline for potential FDA approval depends on Phase 3 trial results, which are expected to read out over the next one to two years.

Who Is Each Medication Best For?

Semaglutide May Be Best For:

• Individuals who want a well-studied, FDA-approved medication with extensive long-term safety data
• Patients who prioritize cardiovascular risk reduction (supported by the SELECT trial)
• People seeking a medication with established insurance coverage pathways
• Individuals with moderate weight loss goals (10-15% of body weight)
• Patients who value the reassurance of a medication used by millions of people worldwide

Retatrutide May Be Best For (Once Available):

• Individuals who need greater than 15-20% body weight loss
• Patients who have plateaued on semaglutide or tirzepatide
• People with significant metabolic dysfunction who may benefit from the glucagon receptor’s effects on liver fat and energy expenditure
• Individuals with MASH (metabolic dysfunction-associated steatohepatitis) given the glucagon receptor’s role in hepatic fat metabolism
• Patients willing to use a newer medication with less long-term safety data in exchange for potentially greater efficacy

What to Expect During Treatment

Starting Semaglutide

• Weeks 1-4: Starting dose of 0.25 mg weekly; minimal weight loss expected; some GI adjustment
• Weeks 5-16: Gradual dose escalation every 4 weeks; increasing appetite suppression and weight loss; GI side effects most common during this phase
• Months 4-12: Maintenance dose reached; most significant weight loss occurs; symptoms typically stabilize
• Beyond 12 months: Continued weight maintenance with ongoing use; the STEP 5 trial showed sustained 15.2% weight loss at 2 years

Starting Retatrutide (Based on Clinical Trial Protocols)

• Weeks 1-4: Low starting dose; body adjustment period
• Weeks 5-24: Gradual dose escalation to target dose; progressive increase in appetite suppression and energy expenditure effects
• Weeks 24-48: Maximum dose maintained; most dramatic weight loss period; weight loss trajectory still accelerating at this point in Phase 2 data

Personalized Treatment at Rewind Anti-Aging

Choosing the right weight loss medication is not a one-size-fits-all decision. At Rewind Anti-Aging of Miami, we take a personalized approach that considers your complete health profile, weight loss goals, medical history, and individual response to treatment.

Our comprehensive weight loss programs include:

• Medical evaluation and metabolic assessment to identify the best treatment approach
• Personalized medication selection with semaglutide, tirzepatide, and other evidence-based options
• Structured dose titration designed to maximize results while minimizing side effects
• Regular monitoring with bloodwork, body composition tracking, and clinical check-ins
• Nutrition and exercise guidance to optimize body composition and preserve lean mass
• Transition planning as new treatments like retatrutide become available

Whether semaglutide, tirzepatide, or eventually retatrutide is the right fit for your goals, our team provides the medical expertise and ongoing support needed for lasting results. Book a consultation with Rewind Anti-Aging to discuss which treatment approach is right for you.

Related Articles

• Retatrutide vs Tirzepatide: Which Peptide Is Better?
• How Does Retatrutide Work? The Triple-Action Peptide Explained
• Difference Between Tirzepatide and Semaglutide

References

1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a Phase 2 trial. N Engl J Med. 2023;389(6):514-526. PubMed
2. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. PubMed
3. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232.
4. Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference, and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242-1251.
5. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2015;22(6):956-970.
6. Pocai A. Action and therapeutic potential of oxyntomodulin. Mol Metab. 2014;3(3):241-251.
7. Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight (STEP 3). JAMA. 2021;325(14):1403-1413.
8. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nat Med. 2022;28(10):2083-2091.

---

Ready to explore your weight loss options? Rewind Anti-Aging of Miami offers personalized semaglutide therapy and other advanced treatments with comprehensive monitoring and support. Schedule a consultation →

This article is for informational purposes only and does not constitute medical advice. Retatrutide is an investigational medication not yet approved by the FDA. Always consult with a qualified healthcare provider before starting any weight loss treatment.